BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...

Incorporating perioperative durvalumab into treatment with neoadjuvant chemotherapy and radical cystectomy prolongs EFS and OS in patients with MIBC.

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...